This company has not started trading yet. The live 5-factor QL signal switches on automatically on its first session.
Aspen Neuroscience, Inc. is a leading, clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need. Our lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson’s disease (PD).
From Aspen Neuroscience, Inc.'s Form S-1/A filed with the SEC on 2026-10-26. The issuer's own words — QuantLogix does not paraphrase it.
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, as follows: • approximately $8.0 million to continue funding the Phase 1/2a ASPIRO trial evaluating sasineprocel in patients with sporadic and genetic PD; • approximately $110.0 million to initiate and fund a Phase 3 trial evaluating sasineprocel in patients with sporadic and genetic PD, with plans to initiate such Phase 3 trial prior to the completion of the Phase 1/2a ASPIRO trial; • approximately $4.0 million…
From Aspen Neuroscience, Inc.'s Form S-1/A filed with the SEC on 2026-10-26. Quoted from the prospectus.
| Net loss | $62,100,000 | year ended December 31, 2025vs $48,600,000 · year ended December 31, 2024 | +27.8% |
|---|
Figures as stated in the prospectus, not QuantLogix estimates. From Aspen Neuroscience, Inc.'s Form S-1/A filed with the SEC on 2026-10-26.
From Aspen Neuroscience, Inc.'s Form S-1/A filed with the SEC on 2026-10-26. Extraction is deterministic — the same filing always produces the same score; 429k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.
Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.